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Abstract
Background: Conditional gene activation is an efficient strategy for studying gene function in genetically modified
animals. Among the presently available gene switches, the tetracycline-regulated system has attracted considerable
interest because of its unique potential for reversible and adjustable gene regulation.
Results: To investigate whether the ubiquitously expressed Gt(ROSA)26Sor locus enables uniform DOX-controlled
gene expression, we inserted the improved tetracycline-regulated transcription activator iM2 together with an iM2
dependent GFP gene into the Gt(ROSA)26Sor locus, using gene targeting to generate ROSA26-iM2-GFP (R26
t1Δ)
mice. Despite the presence of ROSA26 promoter driven iM2, R26
t1Δ mice showed very sparse DOX-activated
expression of different iM2-responsive reporter genes in the brain, mosaic expression in peripheral tissues and
more prominent expression in erythroid, myeloid and lymphoid lineages, in hematopoietic stem and progenitor
cells and in olfactory neurons.
Conclusions: The finding that gene regulation by the DOX-activated transcriptional factor iM2 in the Gt(ROSA)
26Sor locus has its limitations is of importance for future experimental strategies involving transgene activation
from the endogenous ROSA26 promoter. Furthermore, our ROSA26-iM2 knock-in mouse model (R26
t1Δ) represents
a useful tool for implementing gene function in vivo especially under circumstances requiring the side-by-side
comparison of gene manipulated and wild type cells. Since the ROSA26-iM2 mouse allows mosaic gene activation
in peripheral tissues and haematopoietic cells, this model will be very useful for uncovering previously unknown or
unsuspected phenotypes.
Backround
To understand the detailed function of particular genes
we must be able to translate analytical and database
information into experimental model systems. In this
respect, the laboratory mouse can be used as a higher
vertebrate model that permits the application of genetic
tools for the in vivo analysis of gene function. Since
constitutive, global expression of transgenes is often asso-
ciated with embryonic lethality or unwanted pleiotropic
effects, tight postnatal transgene regulation is the method
of choice. Furthermore, correlations between phenotypes
and ‘ON’ and ‘OFF’ states of the regulated gene can
provide reliable cues for understanding gene-function.
However, to ensure that the observed phenotypes are
correlated with the gene function under investigation the
reservoir of genetic tools has to be carefully evaluated.
Over the last decade the tetracycline (tet)-regulatory
system has been extremely useful for generating condi-
tional transgenic mouse models (for reviews see [1-3]).
Besides its fundamental appeal as an established reversi-
ble regulatory system in mice, tet ‘ON/OFF’-systems
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unique potential for reversible gene regulation, with the
additional advantage of allowing adjustment of trans-
gene expression levels through the administration of
predetermined amounts of the pharmacological inducer
doxycycline (DOX) [4-6]. The graded response of tet-
regulated transgenes thus provides the unique opportu-
nity to analyze gene dosage effects in living animals.
Although a large collection of tet-controlled transgenic
mice suitable for studying gene function in many differ-
ent cell types is available to the scientific community
(http://www.zmg.uni-mainz.de/tetmouse for an electro-
nically searchable database), no comprehensive analysis
of a tet-regulatory effector line using the ubiquitously
expressed Gt(ROSA)26Sor gene locus has been pub-
lished. Therefore, we generated a tet ‘ON’ knock-in
mouse line (R26
t1Δ) containing the iM2 reverse DOX-
dependent transactivator coding region [7] and an iM2
responsive GFP gene at the Gt(ROSA)26Sor gene locus.
Analysis of R26
t1 mice using different iM2-responsive
reporter strains revealed mosaic induction of conditional
reporter gene activity in peripheral organs and in hema-
topoietic cells. No substantial iM2 reporter gene activa-
tion was detected in most parts of the adult brain with
the exception of the bulbus olfactorius and, to a lesser
extent, the striatum.
Results
Generation of the ROSA26-iM2PtetGFP knock-in mouse
By gene targeting, we inserted the iM2 transactivator
gene [7], a loxP flanked neo/ura selection marker and a
Ptet-controlled GFP followed by a human growth hor-
mone polyadenylation signal into the XbaIs i t eb e t w e e n
e x o n 1a n d2o ft h eGt(ROSA)26Sor locus ([8]; Figure
1A). A splice acceptor sequence (SA) identical to the
one used in the original lacZ-gene-trap allele [9] was
inserted 5’-prime to the iM2 start codon to facilitate the
processing of ROSA26 promoter controlled transcripts
[10]. A synthetic intron in the 5’UTR of GFP was used
to stabilize the Ptet transcript and an additional human
growth hormone polyadenylation sequence was inserted
in front of Ptet to avoid transcriptional interference
between the ROSA26 and Ptet promoter. The recombi-
nant gene locus Gt(ROSA)26t1 (R26
t1) (Figure 1A) is
thus expected to express the iM2 transactivator from
the endogenous ROSA26 promoter. In the presence of
DOX, iM2 can activate the Ptet-promoter, which in turn
can be visualized by the expr e s s i o no fG F P .T h u s ,c o -
localisation of both iM2 and the Ptet responder GFP
genes in the same locus facilitates a rapid fluorescent
screen for monitoring the Ptet-activity in single cells.
The generation of the R26
t1 gene locus by homolo-
gous recombination in the genome of ES cells was pre-
screened by PCR and confirmed by Southern blotting
(Figure 1B). Six independent ES cell clones with inser-
tion of the inducible iM2-PtetGFP module at the Gt
(ROSA)26Sor locus were identified (Figure 1B). All six
ES cell clones showed DOX-inducible GFP fluorescence
(Figure 1B) and ES cell clone 64 was used for blastocyst
injections to generate the ROSA26-iM2-PtetGFP mouse
line, designated R26
t1. Removal of the loxP flanked neo/
ura selection cassette was performed by in vivo excision
using the deleter-cre strain [11] thus generating the
R26
t1Δ allele in a sub-line (R26
t1Δ)l a c k i n gt h en e o / u r a
genes (Figure 1C).
In embryos, spleen, kidney and liver of R26
t1Δ mice
rapid amplification of cDNA ends (RACE) revealed that
R26
t1Δ transcripts contained 3’-exon1 sequences of
ROSA26 transcript variant 2 (Figure 1C). Since the
ROSA26 promoter and exon1 of splice variant 2 were
not present in the targeting vector, this finding confirms
that the recombined R26
t1Δ gene locus drives iM2
expression from the ROSA26 promoter. Thus the pre-
sence of splice variant exon1 at the 5’-end of iM2 tran-
scripts provides additional proof for successful iM2 gene
module insertion into the Gt(ROSA)26Sor gene locus.
Currently, we cannot resolve why the exon1 splice
variant 1 was not detected in our analysis. Because
sequence alteration at the exon1 splice donor site could
be excluded by sequencing it is possible that the pre-
sence of a second artificial intron in front of the iM2
coding sequence might influence the maturation of the
primary R26
t1Δ transcript.
The presence of the neo spacer sequence and the gene
dosage effect on the DOX regulated GFP in the ROSA26-
iM2-GFP locus
The iM2 activity in R26
t1Δ and R26
t1Δ/t1Δ mice was
determined by GFP-detecting immunoblots of total pro-
tein extracts obtained from different tissues (Figure 2).
Calnexin was used as loading control and found to be
differentially expressed in various tissues. As shown in
Figure 2, in the absence of DOX no GFP-specific signal
was detected in any tissue of all three genotypes as
exemplified for muscle tissue of R26
t1Δ and R26
t1Δ/t1Δ
mice. This directly indicates that the Ptet promoter is
not activated after insertion into the Gt(ROSA)26Sor
locus by read through transcripts or promoter interfer-
ence. When mice were exposed to DOX, we detected
weak GFP signals only in thymus extracts from R26
t1
mice (not shown). However, in R26
t1Δ mice highest GFP
levels were obtained following DOX induction in spleen,
thymus, muscle and testis (Figure 2). Thus - as noticed
earlier and described in detail for the Gt(ROSA)26Sor
gene locus in ES cells [12] - removal of the NEO gene
improved gene expression at the targeted locus. In
homozygous R26
t1Δ/t1Δ mice GFP expression was even
further augmented in muscle and testis but this increase
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Page 2 of 13Figure 1 The gene targeted R26
t1Δ allele controls the expression of DOX-inducible transcription from the endogenous promoter of
the Gt(ROSA)26Sor locus. A) Gt(ROSA)26Sor and Gt(ROSA)26t1 (R26R
t1) loci. Exons are indicated as grey boxes; light grey show alternative
spliced exons. Genetic elements inserted at the first XbaI site in intron1 of Gt(ROSA)26Sor are given in coloured boxes: first (yellow), the
adenovirus major late splice acceptor sequence followed by the small intron of the adenoviral tripartite leader and the iM2 coding region
terminated by the human growth hormone polyadenylation signal (hgh_pA); second (red), a loxP site (black triangles) flanked neomycin/uracil
selection cassette [36] terminated by hgh_pA; third (green), the PtetO5-GFP gene module terminated by SV40_pA. Diagnostic restriction sites are
indicated (E = EcoRV, Xh = XhoI, X = XbaI, P = PacI, A = AscI). The transparent green bar represents the chromosomal region covered by the
targeting vector. Red-framed black boxes below R26R
t1 mark positions of Southern blot probes that detect restriction fragments given as red
lines in kilo bases (kb). B) Left: Southern blots of genomic DNA isolated from wild type (WT) and PCR-preselected ES cell clones 27, 48, 60, 64, 65
and 67. Right: Images of R26
t1 ES cells show DOX-dependent GFP expression. C) Schematic representation of the R26R
t1Δ allele after Cre
mediated removal of neo/ura at the R26
t1 allele (symbols are as in 1A). Transcriptional starts of the ROSA26 and Ptet promoter are indicated by
arrows. Below the 5’-RACE identified exons (solid lines) and introns (dashed lines) of the iM2 encoding R26
t1Δ mRNA are given. Below the 5’ ends
of mRNA from embryos, kidney liver and spleen are aligned to Gt(ROSA)26Sor transcript variants of the database (NCBI Accession numbers are
indicated).
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Page 3 of 13Figure 2 Expression of the GFP reporter gene in adult R26t
1Δ and homozygous R26
t1Δ/t1Δ mice. Western blot analysis of muscle extracts
from wild-type (WT), R26
t1Δ and R26
t1Δ/t1Δ mice three to five month of age. Upper part: No GFP-specific signal could be detected in muscle
without DOX administration. The very same blot was probed for calnexin (Cal.) and the result is shown below the GFP-specific signal. Lower part:
Western blot analysis of GFP (four upper lanes) and calnexin (four lower lanes) expression in spleen, thymus, muscle and testis extracts from
DOX-induced wild-type (WT), heterozygous (R26
t1Δ) and homozygous (R26
t1Δ/t1Δ) mice. The GFP and calnexin signals were obtained from the
same blot. For reasons of simplicity the calnexin loading control and the GFP signal are aligned and pictured as one group. Animals were
treated with DOX for 3 weeks prior analysis.
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Page 4 of 13was not obvious in spleen and thymus. However, since
spleen and thymus represent tissues with high GFP
expression in activated R26
t1Δ animals, a two-fold
increase in R26
t1Δ/t1Δ mice might have escaped our
semi-quantitative analysis. Thus it seems that for tissues
with low levels of iM2 controlled genes a gene dosage
increase of iM2 and the Ptet gene(s) or both can be
beneficial for the expression level of Ptet controlled
genes.
Characterisation of the R26
t1Δ effector mouse in
hematopoietic tissues
To determine to what extend different hematopoietic
cell types of R26
t1Δ mice can implement DOX-regulated
transgene expression, DOX-induced and non-induced
R26
t1Δ mice were analyzed by flow cytometry. As
expected, no GFP-expressing hematopoietic cells were
found in R26
t1Δ mice never exposed to DOX (data not
shown). In DOX-treated R26
t1Δ littermates GFP-expres-
sing cells were present in all analyzed hematopoietic
lineages (Figure 3). Based on their expression for CD71
and Ter119 four subpopulations representing different
red blood cell maturation steps could be established
(erythrocytes, maturation stage I to IV). Compared to
the immature early proerythroblasts (I, 11.01% ± 6.4),
GFP
+ cells were less abundant in more mature erythroid
populations (II-IV). Analysis of bone marrow granulo-
cytes demonstrated that about one fourth (24.15% ±
8.37) of the less mature CD11b
+/Gr1
low population
expressed GFP whereas the more differentiated
CD11b
+/Gr1
high population contained only few GFP-
expressing cells (2.05% ± 1.43). In the spleen of DOX-
induced R26
t1Δ mice 10.64% ± 7.16 of the granulocytes
were GFP positive (CD11b
+/Gr1
+ splenic granulocytes).
Within the megakaryocytic lineage CD41
+/c-Kit
+
megakaryocytic progenitors contained 19.69% ± 13.07
GFP-expressing cells while within the CD41
+/c-Kit
-
population of more mature megakaryocytes only 3.39%
± 3.9 of cells expressed GFP. Similarly, flow cytometric
analysis of CD23
+ mast cells revealed the presence of a
fraction of GFP-expressing cells (11.58% ± 5.94). GFP
+
cells were also present in the lineage negative (lin
-),
c-Kit- and Sca-1-expressing population of cells that con-
tains hematopoietic stem cells and progenitors (12.21%
± 7.68, LKS stem cells). From the analyzed B-lympho-
cytes a high percentage of B220
+/CD19
- pre-pro B cells
(42.6% ± 11.54), re-circulating B220
+/CD19
low (25.48% ±
17.04) and B220
+/CD19
high new produced (21.41% ±
11.05) B-cells expressed the GFP reporter gene. Within
the thymus GFP-expressing cells were found in CD4
+/
CD8
+ double positive cells (11.51% ± 6.32) and also in
CD4 single positive (6.01% ± 2.88) and CD8 single posi-
tive (12.14% ± 6.38) thymocytes. These results indicate
that the expression of the R26
t1Δ controlled iM2
transactivator can activate the co-localized Ptet-GFP
transgene in erythroid, myeloid, lymphoid lineages and
also in lin
-/c-Kit
+/Sca-1
+ hematopoietic stem and pro-
genitor cells in presence of DOX. Our findings further
demonstrate that the percentages of Ptet-GFP reporter
gene expressing cells are highly variable in different
hematopoietic cell types of R26
t1Δ.
Evaluation of the R26
t1Δ effector mouse in the brain
Several Gt(ROSA)26Sor targeted Cre-reporter mouse
lines are available and have been successfully used to
monitor Cre-induced transgene activation patterns in
different cell types of the mouse brain [8,10,13-15].
However, results obtained with the endogenous
ROSA26 promoter used for conditional gene expression
in the brain were not consistent [16-19]. To clarify the
potential of the R26
t1Δ mice for conditional transgene
expression in neural tissues, protein extracts from differ-
ent brain areas of R26
t1Δ and R26
t1Δ/t1Δ mice were ana-
lyzed by Western blotting (Figure 4A). A very strong
DOX-dependent GFP-specific signal was present in pro-
tein extracts from the olfactory bulb of R26
t1Δ mice. In
contrast, no GFP signal was detected in any other brain
region after DOX-induction as shown for the mesence-
phalon, the hippocampus, the cortex and the cerebellum
(Figure 4A). In homozygous, DOX-induced R26
t1Δ/t1Δ
mice weak GFP expression was found in cerebellar
extracts and to an even lower extent in the mesenence-
phalon, the hippocampus and the cortex. The GFP
signal in the olfactory bulb was dramatically increased
and ten fold less protein was loaded for immunoblotting
to obtain a comparable GFP signal for the calnexin load-
ing control.
Immunohistochemistry of sagittal brain sections con-
firmed strong, DOX-depend e n tG F Pe x p r e s s i o ni nt h e
olfactory bulb of R26
t1Δ and R26
t1Δ/t1Δ mice (Figure 4B).
However, the GFP-staining was restricted to the glomer-
uli formed between axonal projections of olfactory
receptor neurons (ORNs) and dendritic processes from
mitral cells of the olfactory bulb. Since the cell bodies of
mitral cells within the olfactory bulb were negative for
GFP immunostaining, the GFP signal in the olfactory
bulb is derived from ORNs, which have their cell bodies
in the nasal cavity of the olfactory epithelium outside
the brain. Hardly any GFP-positive cells were apparent
in brain sections of DOX-induced R26
t1Δ and R26
t1Δ/t1Δ
mice; with the exception of sparse GFP-positive cells
in the striatum and hypothalamus of homozygous
R26
t1Δ/t1Δ mice (Figure 4B) directly confirming the
immunoblot results (Figure 4A). Thus, as noticed in
peripheral tissues, the increased gene dosage of the
R26
t1Δ/t1Δ allele improved the expression of GFP in the
brain. Our findings therefore suggest that in heterozy-
gous R26
t1Δ mice, a critical threshold of DOX-activated
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Page 5 of 13Figure 3 The R26
t1Δ mouse line directs transgene expression to adult blood cells and hematopoietic stem and progenitor cells.
(A) Expression of GFP in different hematopoietic cells is given as mean values ± standard deviations in a bar graph. Analyzed cell-lineages are
shown on the right. For conditional GFP activation three month old mice were exposed to DOX for fourteen days prior to the analysis. No GFP
activation was detected in genetically identical littermates not exposed to DOX (not shown). At least four different animals from DOX-induced and
non-induced littermate controls were analyzed for hematopoietic lineage determination. (B) In the right column relative percentages of GFP
+ cells
are indicated as mean values ± standard deviations. Lineage-specific markers are specified in the central white column. Roman numerals refer to
different maturation stages of red blood cell development: I, proerythroblasts; II, basophilic erythroblasts; III, late basophilic erythroblasts and
chromatophilic erythroblasts; IV, orthochromatophilic erythroblasts. GFP, green fluorescent protein; LKS, lineage
-/c-Kit
+/Sca1
+.
Wörtge et al. BMC Developmental Biology 2010, 10:95
http://www.biomedcentral.com/1471-213X/10/95
Page 6 of 13iM2 for transcriptional activation of Ptet-GFP is not
reached in most cells of the brain.
In order to increase the level of active transactivator in
t h eb r a i n ,w eg e n e r a t e dR 2 6
t1Δ mice that express the
DOX-activated transcription factor tTA in the forebrain
by breeding R26
t1Δ and TgCamKII-tTA mice [20]. Com-
pared to R26
t1Δ and R26
t1Δ/t1Δmice, adult R26
t1Δ/
TgCamKII-tTA animals showed many more GFP-posi-
tive cells in brain regions with strong TgCamKII-tTA
expression including striatum, cortex and glomeruli
of the olfactory bulb thus favouring the hypothesis
that detectable brain-specific GFP expression needs a
certain threshold of DOX-induced activator molecules
(Figure 4C). However, only a few pyramidal cells in hip-
pocamal layer CA1 demonstrated GFP expression (Fig-
ure 4C) despite the high activity of tTA in those brain
regions [20,21]. This lack of optimal tTA mediated Ptet-
GFP gene activation in the R26
t1Δ locus might be caused
by a negative interference of the CamKII promoter
expressed tTA and R26
t1Δ encoded iM2 forming inactive
heterodimers. The formation of inactive heterodimers
is supported by mice expressing iM2 and tTA together
with a Ptet-GFP responder transgene TgPtetbi-GFP-
GluA1/nlacZ [21]. As described by Mack et al., TgCam-
KII-tTA/TgPtetbi-GFP-GluA1/nlacZ mice show
high numbers of GFP positive cells in the forebrain
Figure 4 Ptet-GFP expression of the Gt(Rosa)26t1Δ(R26t
1Δ) locus is controlled by active iM2 and tTA in the brain of adult mice.
(A) Western blots for GFP and calnexin (loading control) of different brain regions in heterozygous (left, R26
t1Δ) and homozygous (right, R26
t1Δ/t1Δ)
mice, raised and kept in the presence of DOX. In R26
t1Δ/t1Δ mice the intensity of the GFP signal in the olfactory bulb augmented and was adjusted
by shorter exposure time and loading less sample than for other brain tissues. For the R26
t1Δ/t1Δ OB lane (+DOX) a shorter exposure time is shown.
(B) Immunohistochemical analysis of GFP expression in the OB, Str and Hyp of DOX-treated heterozygous R26
t1Δ (left panel) and homozygous
R26
t1Δ/t1Δ mice (right panel). Induced animals were raised and kept in the presence of DOX. (C) CamKII-induced GFP immunohistochemistry in OB,
Str, Cx and Hc of R26
t1Δ mice harbouring the additional TgCaMK2-tTA transgene in the absence of DOX (-DOX). (D) GFP immunohistochemistry
showing very strong CaMK2-tTA-activated GFP-GluA1 expression in Str and Hc in mice harbouring both the TgCaMK2-tTA and TgPtetbi-GFP-GluA1/
nlacZ transgenes (left). Weaker GFP-GluA1 expression was apparent in brains of DOX-untreated mice (right), when in addition to the TgCaMK2-tTA
and TgPtetbi-GFPGluA1/nLacZ transgenes the R26
t1Δ allele was present. Striatum (Str), cortex (Cx), mesencephalon (Mc), cerebellum (Cb),
hypothalamus (Hyp), hipocampus (Hc), stratum pyramidale (Py), stratum radiatum (Ra). Black arrows indicate GFP expression. Pictures in B - D were
colour adjusted in Photoshop. The scale bars for B, C and D represent 0.5 mm.
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Page 7 of 13(Figure 4D, left). However, in littermate animals in addi-
tion harbouring the R26
t1Δ allele, the GFP signal drama-
tically dropped (Figure 4D, right) demonstrating
reduced activity of the tTA transactivator in presence of
the R26
t1Δ allele. In summary, our results indicate that a
certain threshold level of iM2 expression is needed to
activate Ptet promoters and provide direct evidence that
the observed lack of Ptet-mediated GFP activation in
DOX induced R26
t1Δ mice might not just be the result
of poor penetration of DOX through the blood brain
barrier.
Activation of R26
t1Δ controlled expression of Ptet
regulated transgenes is DOX-dependent and
inhomogeneous
To further evaluate the functional capability of iM2 in
R26
t1Δ mice, we recruited two different Ptet-transgenic
mouse lines. First, a transgenic mouse line co-expressing
Ptet-controlled Wnt1 and luciferase (TgPtet-Wnt1-
IRES-luciferase) [22] to detect very low levels of trans-
gene induction by non-invasive bioluminescence
imaging [23]; second, a Ptetbi-controlled GFP/lacZ line
for cellular resolution of iM2 activity (TgPtetbi-GFP/
lacZ) (Figure 5).
Compound R26
t1Δ/TgPtet-Wnt1-IRES-luciferase mice
were either treated with DOX in the drinking water or
were never exposed to DOX and after luciferin injection
bioluminescence levels were recorded (Figure 5A).
DOX-exposure during three days induced significant
levels of luminescence whereas no bioluminescence
signal was monitored in mice never exposed to DOX.
Consistent with the previously reported variable levels
of transgene expression from the Gt(ROSA)26Sor locus
in different adult mouse tissues [16,17,24], the lumines-
cence was not uniformly distributed in DOX-induced
R26
t1Δ/TgPtet-Wnt1-IRES-luciferase mice. This inhomo-
geneous luciferase activity pattern thus confirms our
immunoblot observation that the R26
t1Δ locus leads to
highly variable Ptet-transgene expression.
Next, R26
t1Δ induced Ptet-gene activation was visua-
lized on a cellular level in compound R26
t1Δ/TgPtetbi-
GFP/lacZ mice by X-Gal staining (Figure 5B). As
expected, no b-galactosidase (b-gal) expressing cells
were detected without DOX treatment (data not
shown). In line with the DOX-dependent induction of
luciferase expression (Figure 5A), compound R26
t1Δ/
TgPtetbi-GFP/lacZ animals treated for two weeks with
DOX showed lacZ reporter gene activity in skin, ton-
gue, colon, small intestine, pancreas, lung, kidney, tes-
tis and liver. Interestingly, b-gal expression in these
organs was restricted to subsets of cells. No b-gal
+
cells were detected in heart, bladder and stomach
(Figure 5B).
Taken together our results indicated that the expres-
sion of conditional Ptet transgenes can be tightly regu-
lated with the R26
t1Δ allele and that the R26
t1Δ mouse
Figure 5 Conditional reporter gene activation with the R26
t1Δ effector mouse reveals no background activity and varies in peripheral
tissues of adult mice. (A) Whole-body bioluminescence images of compound R26
t1Δ/TgPtet-Wnt1-IRES-luciferase mice showing activation of
luciferase after DOX exposure (right mouse, +DOX). No luciferase signal was detected in genetically identical littermates not exposed to DOX
(left mouse, -DOX). The scale shown measured photon counts translated into pseudo-colours; red indicating high and blue low luciferase
activity. For luciferase gene activation animals were treated for three days with 3 mg DOX/ml in the drinking water. (B) X-Gal staining of
representative cryostat sections from different organs of induced double transgenic R26
t1Δ/TgPtetbi-GFP/lacZ mice. To conditionally activate
transgene expression, compound animals were exposed to 3 mg DOX/ml drinking water for two weeks. The indicated organs were dissected
and analysed by X-Gal staining. Skin (Sk), tongue (To), colon (Co), small intestine (SI), heart (He), pancreas (Pa), bladder (Bl), lung (Lu), kidney (Ki),
testis (Te), liver (Li), stomach (St). The scale bar represents 200 μm.
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number of peripheral tissues.
Discussion
The promoter of the Gt(ROSA)26Sor locus is frequently
used for ubiquitous expression of reporter genes in the
mouse. These animal models represent valuable tools
for conducting conditional gene expression studies.
However, it is debated whether the endogenous promo-
ter of the Gt(ROSA)26Sor locus can direct conditional
transgene activation to all tissues of adult mice [16-19].
Now we provide additional information by a qualita-
tive and quantitative analysis of a gene targeted mouse
line (R26
t1Δ)t h a tc o n t a i n st h eD O X - i n d u c i b l ei M 2
transactivator together with an iM2-dependent GFP
gene inserted into the Gt(ROSA)26Sor locus. We could
show that after gene targeting the ROSA26 promoter
drives expression of the inserted transcriptional activator
gene in several tissues of R26
t1Δ mice. In embryo, liver,
spleen and kidney exon1 of the ROSA26 transcript var-
iant 2 was used in iM2 transcripts. If and to what extent
exon1 of transcript variant 1 is used in iM2 transcripts
cannot be concluded from our data, since the conducted
RACE analysis did not provide a quantitative analysis of
all transcripts of the ROSA26 promoter in R26
t1Δ mice.
More importantly, exon1 transcript variant 2 is located
outside of our targeting vector providing additional evi-
dence that the Gt(ROSA)26Sor targeting was successful.
Since electroporation with our targeting vector provided
several randomly inserted GFP expressing ES cell clones,
all containing transcriptional start sites in the short arm
of the targeting vector (data not shown), the transcript
analysis conducted here provides direct experimental
proof for the ROSA26 promoter-specific transcription of
the iM2 transgene and can be used as a functional test
for demonstrating correct gene transcription of the rear-
ranged locus.
In gene targeted mice ROSA26 promoter controlled
iM2 activity was evaluated by monitoring (i) the co-
inserted downstream Ptet-GFP reporter gene, (ii) the
conditional induction of the TgPtet-Wnt1-IRES-lucifer-
ase [22] or the TgPtetbi-GFP/lacZ [25] transgenes. All
three different reporter systems, including the very sensi-
tive luciferase reporter, demonstrated convincingly that
the R26
t1Δ allele permits gene induction with no back-
ground activity of the iM2-controlled gene in the non-
induced state. These results indicate that illegitimate
activation of Ptet-GFP in the Gt(ROSA)26Sor locus by
read through transcripts or promoter interference does
not take place. Our experiments also demonstrate that
different iM2 responder genes could be induced by DOX.
However, the responder gene expression was moderate
and highly variable between and within different tissues.
We detected conditional transgene expression in a subset
of cells from skin, tongue, colon, small intestine, pan-
creas, lung, kidney, testis and liver, whereas some organs
like heart, bladder and stomach had no detectable trans-
gene induction.
In addition to the localization of conditionally acti-
vated cells within peripheral organs, we provide a
detailed picture of R26
t1Δ encoded iM2 expression in
the hematopoietic system. Although for the initially
gene-trapped b-Geo ROSA26 mouse strain the expres-
sion of the integrated b-Geo reporter gene in immature
red blood cells, lymphoid and myeloid lineages was
found [24] and several ROSA26-driven reporter mouse
strains exist and have been used in hematopoietic
tissues [8,10,13-15], no detailed information about the
potential and tissue-specificity of ROSA26-driven tet
‘ON/OFF’ mouse systems is available for hematopoietic
tissues. To provide this missing information, we ana-
lyzed induced R26
t1Δ mice by flow cytometry. The
results of these experiments indicate that the R26
t1Δ
allele is active in different adult blood cell types and
also in the lineage negative c-Kit- and Sca-1-expressing
(LKS) population, which contains hematopoietic stem
cells and progenitors.
In contrast to the peripheral tissues and the hemato-
poietic system, in cells of the central nervous system the
activity of the R26
t1Δ encoded iM2 was barely detect-
able. Olfactory receptor neurons projecting to glomeroli
of the olfactory bulb showed the highest DOX-inducible
iM2 activity in homozygous R26
t1Δ/t1Δ and heterozygous
R26
t1Δ mice. In whole brain extracts, however, only low
GFP protein levels could be detected in mesencephalon,
hippocampus and cortex of DOX-induced homozygous
R26
t1Δ/t1Δ mice. Immunohistochemical staining of brain
sections revealed a few, scattered GFP-expressing cells.
The low levels of functional iM2 appeared to be one
reason for the dysfunction of the R26
t1Δ allele in most
cells of the central nervous system since an increase of
the R26
t1Δ gene dosage in homozygous mice provided
higher GFP expression levels in several brain regions
including the glomeroli of the olfactory bulb. Even more
neurons showed R26
t1Δ-derived GFP expression when
the levels of functional transactivator were increased by
forebrain specific tTA expression using a CaMKII pro-
moter driven transgene [20]. However, GFP expression
was lower than in other transgenic Ptet-GFP responder
mice, most likely due to the presence of the iM2 in
R26
t1Δ animals. The reduced tTA activity in R26
t1Δ gen-
otypes therefore is best explained by the mutual inter-
ference of tTA and rtTA (iM2) heterodimers [26,27]
and can be convincingly visualized by the reduction of
GFP-GluA1 expression in the CA1 pyramidal neurons
of the hippocampus in compound transgenic mice.
Applying a very similar targeting strategy, Bäckman
and colleagues recently generated a ROSA26-rtTA
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ment inserted downstream of a ROSA26-driven rtTA
cassette. Interestingly, DOX-induced adult mice
expressed low Cre mRNA levels and therefore failed to
activate recombination of a floxed reporter gene sug-
gesting that the endogenous ROSA26 promoter might
be too weak for efficiently inducing conditional trans-
gene activation [28]. Besides the low activity of the
endogenous ROSA26 promoter, a second reason for the
poor iM2 activity in the brain might be the blood brain
barrier, which may limit the free accessibility of DOX
for neurons in the brain. However, using intra-cerebral
DOX injection or rAAV virus mediated tTA gene deliv-
ery into the brains of adult R26
t1Δ mice, we failed to
achieve neuronal GFP expression in the injected cortex
or hippocampal areas (data not shown). Thus as
described in previous studies [7] the Ptet promoter
might be subject to epigenetic gene silencing when not
activated during early stages of development. In this
respect it is of note that in all experiments studying the
expression of the R26
t1Δ GFP allele in the brain, we
already applied DOX to the embryo. Similarly, we used
tTA expression to activate the R26
t1Δ encoded GFP in
the forebrain since the CamKII promoter of Tg-Cam-
KII-tTA is transcriptionally active in the mouse brain
during early development [25,29] and thus the Ptet pro-
moter region is still open for transcriptional activation.
Currently, we can not formally exclude the possibility
that, in addition to other effects, the lack of detectable
Ptet activation in the brain might in part be caused by
transcriptional interference, which is known to reduce
or extinguish transcriptional activity of downstream pro-
moters in double gene constructs [30-32] and was
recently described for theC M Va n dt h eR O S A 2 6p r o -
moter in a targeted Gt(ROSA)26Sor locus in ES cells
[12]. However, the fact that the R26
t1Δ-iM2 activation of
transgenic Ptet-responders in trans was limited as well,
and that in the SK3 channel the insertion of a very simi-
lar linked transactivator and responder gene was opera-
tive [33] strongly argues against promoter interference.
In addition, negative expression variation effects of Ptet
caused by its 91 bp fragment from the CMV promoter
can be responsible for the inhomogeneous activity of
the Ptet promoter.
Conclusion
The presented qualitative and semi-quantitative analysis of
our R26
t1Δ m o u s el i n ep r o v i d e sd e t a i l e dd a t ao nt h ei M 2
and Ptet controlled GFP activity, which is a key informa-
tion for future experiments using R26
t1Δ mice. This
knowledge can be useful to guide the experimental design
of particular research projects using DOX-regulated gene
expression. Finally, the here conducted analysis provides
valuable information about the potential of the R26
t1Δ
mouse for activating transgene expression in different tis-
sues and hematopoietic lineages and thus will help to
decide if this mouse model is suitable for a particular
in vivo experiment.
Methods
Construction of the targeting vector
For gene targeting at the Gt(ROSA)26Sor locus we inserted
the coding sequence for the iM2 transactivator (rtTA-M2;
[7]), containing a codon improved version of the tet-indu-
cible M2 transcription factor [34], a loxP flanked neo
selection marker and a Ptet-controlled GFP followed by a
hgh polyadenylation signal into the PacI/AscI site between
exon1 and 2 targeting vector pROSA26PA [8] to generate
plasmid pROSA-iM2. In detail: a plasmid containing the
tri-TAUBi-AF cassette was used as starting material
[35,36]. The unique KpnIa n dClaI sites were removed
from phM2-1 by filling in with Klenow polymerase
followed by ligation. A 120 bp fragment containing the
adenovirus major late transcription splice acceptor
sequence (SA) from the intron1/exon2 boundary was
amplified by PCR from pSAßGal [9] using primer SA-F
(5’-TTTGGCCATACTGGCCTTAATTAATAGGGCG-
CAGTAGT CCAGGG-3’)a n dS A - R( 5 ’-TTTACTAG-
TACTGGAAAGACCGCGAAGAGTT-3’) to introduce a
PacI site upstream of the SA and was inserted into pCR4
(Invitrogen, Karlsruhe, Germany) by TOPO cloning. The
SA fragment was recovered by SfiI and SpeI digestion and
inserted 5’ relative to the adenoviral tripartite leader
sequence [37] to yield phM2-2. Subsequently, a fragment
encompassing the SV40 splice donor-splice acceptor
intron together with the N-terminal part of the humanized
GFP (GFP [38]) expression unit [25] was amplified by PCR
using primers GFP1F (5’-AAGCGCGCAAGCTTATCGA-
TACCGTCGACC-3’)a n dG F P 1 R( 5 ’-GTATTCCAGC
TTGTGGCCGAG-3’). A second fragment including the
C-terminal portion of GFP and the SV40 polyadenylation
signal was amplified by PCR using primer GFP2F
(5’-CTCGGCCACAAGCTGGAATAC-3’)a n dG F P 2 R
(5’-AAGGCCG GCCGGCGCGCCCGTAATACGACT-
CACTATAGGG-3’) to introduce an AscI site between the
SV40 polyadenylation signal and the FseIs i t e .B o t hP C R
fragments were inserted into pCR4 by TOPO cloning.
These two fragments, were excised using BssHI/PflMI and
PflMI/FseI digestion respectively and ligated into the AseI/
FseI sites of phM2-2 to place the GFP expression unit
under the control of the tetracycline-responsive promoter
resulting in the phM2-3 plasmid. This plasmid was then
digested using PacIa n dAscI and cloned into PacIa n d
AscI linearized pROSA-PA (kindly provided by S. Srinivas,
Department of Physiology, Anatomy and Genetics,
Oxford, UK). Plasmid pROSA-PA is a derivative of
pROSA26.1 [10] where the unique XbaI restriction site,
between exon1 and exon2 is replaced by a PacI/SwaI/AscI
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earized with KpnI and subsequently used for
electroporation.
Generation of R26
t1 and R26
t1Δ knock-in mice
The R1 embryonic stem (ES) cell line [39] was electro-
porated with the linearized pROSA-hM2 targeting vec-
tor and G-418-resistant clones were screened for
homologous recombination by PCR with the GC-Rich
PCR system (Roche, Mannheim, Germany) using pri-
mers ROSA-IN (5’-CCTAAAGAAGAGGCTGTGCT
TTGG-3’)a n dS A - I N( 5 ’-CATCAAGGAAACCCTG-
GACTACTG-3’). Furthermore, homologous recombina-
tion of ES cells was analyzed by Southern blotting using
an 80 nucleotide probe [10] located mainly upstream of
the 5’ homology region (5’ rosa probe) and an 624
nucleotide neomycin probe (neo probe). Correctly
recombined ES cell clone 64 was injected into blasto-
cysts to generate chimeric mice. Successful germ-line
transmission and correct integration was confirmed by
PCR, using primers ROSA-IN and SA-IN. For in vivo
excision of the neomycin-resistant cassette, germ-line-
transmitting R26
t1 knock-in mice were crossed to the
deleter-cre strain [11]. Successful excision of the loxP
flanked neo/ura cassette was confirmed by PCR. Geno-
typing was performed using a three primer PCR
approach with oligonucleotides ROSA01 (5’-TTCCCT
CGTGATCTGCAACTCC-3’) as forward primer and oli-
gonucleotides ROSA02 (5’-GCTTCAGATGTGC
CTTGCTCTC-3’)a n dR O S A 0 7( 5 ’-CATCAGACTTC-
TAAGATCAGG-3’) as reverse primers under standard
PCR conditions, yielding products of 565 bp for the Gt
(ROSA)26Sor allele and 916 bp for the R26
t1Δ allele
respectively. Gene targeted mice were generated under
the licence Az.: 35-9185.81/G-74/07 (Regierungspräsi-
dium Karlsruhe, Germany).
Animals
The transgenic mouse lines deleter-Cre, TgPtet-Wnt1-
IRES-luciferase, TgCamKII-tTA, TgPtetbi-GFP/lacZ and
the TgPtetbi-GFP-GluA1/nlacZ have been described pre-
viously [11,20-22,25]. To induce transgene expression
animals were administered a solution of doxycycline
(DOX, Sigma-Aldrich, Taufkirchen, Germany) in water
containing 1% sucrose. For each experiment the exposure
times and DOX concentrations used are specified. DOX
treatment was performed under the licence 35.-9185.82/
A49/06, Regierungspräsidium Karlsruhe. Terminal
experiments under the license MPI/T-15/08 and 177-07/
981-18 Landesuntersuchungsamt Rheinland-Pfalz.
RNA isolation and RACE
Total RNA from mice tissues was homogenized using an
Utra Turrax (IKA, Staufen; Germany) and RNA was
isolated with TRI REAGENT® (Molecular Research Cen-
ter Inc. Cincinnati, OH 45212, USA) followed by phe-
nol/chloroform purification. The 5’ RACE was
performed using the FirstChoice® RLM-RACE kit
(Ambion, Applied Biosystems, Darmstadt Germany)
according to the manufacturer instructions. The 5’ RLM
PCR was performed using in the first reaction the itTA-
race out primer (5’-TCTGTAGGCCTGGTGCC-
CAAGTG-3’) and for the nested PCR the itTA-race in
primer (5’-CCCTTCCAGAGGGCAGAAGTGGGTG-3’)
was used. The PCR products were directly subcloned
into the pCR4-topo vector using TOPO® cloning tech-
nology (Invitrogen, Darmstadt, Germany) and subse-
quently sequenced. Sequences were analyzed using
Lasergene (DNAStar.COM; Madison, Wi, USA).
Sequences for the RACE iM2 transcripts of the R26
t1Δ
allele were annotated to the NCBI database and are
available under the accession number HM748862.
In vivo bioluminescence imaging
DOX-induced (3 mg DOX/ml for three days) and non-
induced compound R26
t1Δ/Ptet-Wnt1-IRES-luciferase
mice were intraperitoneally injected with luciferin
(150 mg/kg body weight, Becton Dickinson, Heidelberg,
Germany) and anesthetized by continuous inhalation
with isofluorane (Merck, Darmstadt, Germany). After
waiting for five minutes to allow distribution of luciferin,
the mice were placed in the chamber of an IVIS Lumina
optical imaging system (Caliper Life Sciences, Rüssel-
sheim, Germany) and bioluminescence levels were
collected for 15 seconds. The signal intensity was scaled
to a pseudocolor image, which was then superimposed
on a grayscale photo of the mice using Living Image
software v. 3.0 (Caliper Life Sciences, Rüsselsheim,
Germany).
Southern and Western blotting
Southern blots were performed employing standard proce-
dures using an outside ROSA26 probe as described pre-
viously [10] and as an internal neomycin-specific (neo)
probe, a 624 bp DNA fragment amplified from the neo
gene with the primers rspneo4 (5’-GGC TATTCGGC
TATGAC TGGGC -3’)a n dr s p n e o 5( 5 ’-GGGTAGC-
CAACGC TATGTCC TG-3’).
For Westen blot analysis proteins were isolated with
an Ultra Turrax in 25 mM HEPES (ph 7,4) containing
protease inhibitors (Complete, EDTA-free; Roche, Man-
nheim, Germany). The homogenates were centrifuged
( 9 0 0g ;1 0m i na t4 ° C )t or e m o v ec e l ld e b r i sa n d
10-25 μg of protein was resolved on a 8-12% SDS-polya-
crylamid gel, transfered onto nitrocellulose membranes
and probed with anti-GFP (Abcam; ab6556 1:5000,
Abcam, Cambridge, UK) and anti-calnexin antibodies
(1:3000, Stressgene, Ann Arbor, USA).
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For immunohistology mice were anesthetized with iso-
fluoran (Abbott, Ludwigshafen, Germany) and perfused
with PBS/4% paraformaldehyde (PFA, Sigma-Aldrich).
The brain was isolated and post fixed in PBS/4%PFA for
an additional 3 to 12 hours. For immunohistochemistry,
40- to 70-μm thick vibratom slices were used. Antibody
staining on floating vibratom sections was performed as
described before [40] using the primary polyclonal anti-
GFP primary antibody (Abcam; ab6556 1:5000) together
with the anti-rabbit antibody coupled to horseradish
peroxidase (Vector Laboratories, 1:600, Vector Labora-
tories, Eching, Germany) as the secondary antibody.
Staining was visualized with 3-3’ diaminobenzidine
(DAB, Fluka GmbH, Deisenhofen, Germany), mounted
on slides and air-dried. DAB-developed slides were cov-
ersliped with Eukitt mounting medium (Kindler GmbH,
Freiburg, Germany). Staining for X-Gal was performed
as previously described [41]. All sections were counter-
stained with fast red (Sigma-Aldrich, Taufkirchen,
Germany). Images were captured using a colour view
digital camera running on an Olympus BX50 WI micro-
scope. Images were digitalized using the analySIS soft-
ware package (Soft Image Systems, Münster, Germany)
and imported into Photoshop.
Flow cytometry
Cells acquisition was performed on a FACSCalibur or
LSRII cytometer (BD) and analyzed using the FlowJo
software (Ashland, USA). For lineage determination cells
were analyzed as previously described [41]. Before flow
cytometry, blood cells from DOX-induced (14 days of
3 mg/ml DOX) or non-induced (normal drinking water)
ROSA26-iM2 R26
t1Δ mice were pre-incubated with PBS
and supplemented with 5% rat serum for 30 minutes to
reduce nonspecific binding. Dead cells were excluded by
7-amino-actinomycin D (Becton Dickinson, Heidelberg,
Germany) staining. For cell staining we used antibodies
(all from Becton Dickinson, Heidelberg, Germany) direc-
ted against the following: CD4 (GK1.5), CD8 (53-6.7),
B220 (RA3-6B2), CD19 (1D3), Gr1 (RB6-8C5), CD11b/
Mac1 (M1/70), Ter119, CD71 (R17 217.1.4), CD41
(MWReg30), c-Kit (2B8), Sca-1 (D7). The CD23 anti-
body was from Southern Biotech, Birmingham, USA.
In all cases, the number of GFP-expressing cells was
determined in four independent experiments analyzing,
each time, a minimum of 5 × 10
5 cells.
Statistical analysis
For statistical data analysis the two-tailed t test was applied
using the Prism4 package for Windows (GraphPad soft-
ware, La Jolla, USA).
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